LTR Pharma (ASX:LTP) has entered into an agreement with Symbion, a leading pharmaceutical wholesaler in Australia, to establish national distribution capabilities for SPONTAN.
Under the agreement, Symbion will provide warehousing, inventory management and nationwide distribution services for SPONTAN through its extensive network of distribution centres servicing over 3,900 pharmacies across Australia.
The non-exclusive agreement commences on 1 March 2025 and includes comprehensive quality assurance, inventory management systems and specialised handling processes tailored to pharmacy requirements.
Key implementation milestones include:
This partnership grants LTR Pharma access to established, scalable pharmaceutical infrastructure, aligning with the company’s strategy to support the early access scheme and prepare for a full-scale commercial launch post- regulatory approvals.
“Partnering with Symbion is a pivotal step in building our commercial infrastructure,” Chairman, Lee Rodne, said.
“Symbion’s extensive distribution network and expertise will ensure seamless access to SPONTAN across Australia. This agreement underscores our commitment to collaboration with industry leaders to establish a reliable supply chain, support the TGA’s early access programme, and prepare for SPONTAN’s anticipated commercial launch.
“Together, we are ensuring the highest standards of pharmaceutical handling and service delivery.”
LTR Pharma’s lead product SPONTAN is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less.
LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.